Pharmacovigilance Certification (PVC) — Questions and Answers

Question 1: Which of the following describes a 'Medication Error' in pharmacovigilance classification?

Any adverse reaction occurring at the recommended dose
A contraindicated drug combination that causes an ADR
A deliberate overdose by the patient
An unintended error in prescribing, dispensing, or administration that may or may not cause harm (Correct answer)

Correct answer: An unintended error in prescribing, dispensing, or administration that may or may not cause harm

A medication error is an unintended failure in the drug treatment process that leads to or has the potential to lead to patient harm, regardless of whether harm actually occurred.

Question 2: What is the significance of peer review in communication & stakeholder management for PVC professionals?

It replaces the need for self-assessment
It is primarily used for disciplinary purposes
It is only relevant for newly certified professionals
It promotes accountability, knowledge sharing, and quality improvement (Correct answer)

Correct answer: It promotes accountability, knowledge sharing, and quality improvement

Peer review promotes accountability, knowledge sharing, and quality improvement by allowing PVC professionals to benefit from collective expertise and identify areas for growth.

Question 3: In signal management, what does the term 'signal validation' refer to?

Notifying regulators of the new safety finding
Assessing whether data support a causal association beyond background noise (Correct answer)
Publishing the signal in a peer-reviewed journal
Confirming the signal in a clinical trial

Correct answer: Assessing whether data support a causal association beyond background noise

Signal validation evaluates whether the available data provide sufficient evidence that the detected association is more than a statistical artifact.

Question 4: According to ICH E2E, which document provides the scientific rationale for proposed pharmacovigilance activities and risk minimization?

Pharmacovigilance System Master File (PSMF)
Periodic Safety Update Report (PSUR)
Development Safety Update Report (DSUR)
Risk Management Plan (RMP) (Correct answer)

Correct answer: Risk Management Plan (RMP)

ICH E2E describes the Risk Management Plan as the document that outlines the safety specification, pharmacovigilance plan, and risk minimization strategy.

Question 5: A medically unqualified consumer reports an ADR directly to a pharmaceutical company. What obligation does the company have regarding this report?

The report must be processed as a valid ICSR if the four minimum elements are present (Correct answer)
No obligation; only healthcare professional reports require action
The company must seek written authorization from the consumer before processing
Consumer reports must be forwarded to the FDA before any internal processing

Correct answer: The report must be processed as a valid ICSR if the four minimum elements are present

Consumer reports must be processed as valid ICSRs when all four minimum elements are present, regardless of whether the reporter has medical qualifications.

Question 6: Which of the following best describes the concept of 'aggregate signal detection' under GVP Module IX?

Using disproportionality analysis only on clinical trial datasets
Detecting safety signals solely from individual spontaneous reports in EudraVigilance
Identifying new safety information from cumulative data across multiple sources including literature, registries, and spontaneous reports (Correct answer)
Reviewing each ICSR individually as it is received without data pooling

Correct answer: Identifying new safety information from cumulative data across multiple sources including literature, registries, and spontaneous reports

Aggregate signal detection involves systematic review of cumulative data from spontaneous reports, clinical trials, literature, registries, and other sources to identify new safety signals.

Question 7: What is the primary purpose of regulatory compliance & legal framework in the context of Pharmacovigilance Certification?

To replace established industry guidelines
To reduce organizational costs exclusively
To ensure consistent quality and professional accountability (Correct answer)
To eliminate the need for ongoing training

Correct answer: To ensure consistent quality and professional accountability

Regulatory Compliance & Legal Framework in Pharmacovigilance Certification primarily ensures consistent quality and professional accountability, forming the foundation of competent practice in this field.

Question 8: Which of the following best describes a key competency required for communication & stakeholder management in PVC certification?

Critical thinking and evidence-based decision making (Correct answer)
Memorization of all relevant regulations verbatim
Delegation of all complex tasks to supervisors
Ability to work independently without any oversight

Correct answer: Critical thinking and evidence-based decision making

Critical thinking and evidence-based decision making is essential for communication & stakeholder management, as professionals must analyze situations and apply knowledge appropriately.

Question 9: When a conflict arises between standard procedures and a unique situation in Post-Marketing Surveillance, what should a PVC professional prioritize?

Strict adherence to written procedures without exception
Safety and ethical obligations while seeking expert consultation (Correct answer)
The most cost-effective solution available
The preference of the client or stakeholder

Correct answer: Safety and ethical obligations while seeking expert consultation

Safety and ethics always take priority in Post-Marketing Surveillance. When standard procedures don't adequately address a unique situation, consulting with experienced colleagues or supervisors ensures both safety and professional standards are maintained.

Question 10: What ethical consideration is most relevant to communication & stakeholder management in PVC practice?

Maintaining confidentiality and acting in the best interest of stakeholders (Correct answer)
Following only those rules that are convenient
Avoiding all professional development activities
Prioritizing personal advancement over professional duties

Correct answer: Maintaining confidentiality and acting in the best interest of stakeholders

Maintaining confidentiality and acting in the best interest of stakeholders is the cornerstone ethical consideration for communication & stakeholder management in professional practice.

Question 11: Under FDA regulations, which entity is primarily responsible for submitting post-marketing safety reports including 15-day Alert Reports?

The NDA/BLA holder (marketing authorization holder) (Correct answer)
The clinical investigator
The prescribing physician
The IRB or ethics committee

Correct answer: The NDA/BLA holder (marketing authorization holder)

The NDA or BLA holder bears primary regulatory responsibility for post-marketing pharmacovigilance, including 15-day expedited safety reports.

Question 12: When a regulatory agency requests a 'benefit-risk communication plan' during a product review, what is its primary goal?

To satisfy post-marketing commitment timelines
To train sales representatives on product features
To ensure patients and prescribers understand risks and benefits to make informed decisions (Correct answer)
To document manufacturing quality standards

Correct answer: To ensure patients and prescribers understand risks and benefits to make informed decisions

A benefit-risk communication plan is designed to convey the benefit-risk profile clearly to patients and healthcare providers to support informed decision-making.

Question 13: Which standard of practice is MOST important for ensuring quality in Risk Management Planning?

Using the most advanced technology available regardless of need
Minimizing documentation to focus on practical work
Strictly adhering to the same procedure in every situation
Following evidence-based protocols while adapting to specific circumstances (Correct answer)

Correct answer: Following evidence-based protocols while adapting to specific circumstances

Evidence-based protocols provide a foundation of proven practices, but effective Pharmacovigilance professionals must also adapt their approach based on specific circumstances and individual case needs within Risk Management Planning.

Question 14: What is the primary purpose of professional standards & ethics in the context of Pharmacovigilance Certification?

To reduce organizational costs exclusively
To replace established industry guidelines
To ensure consistent quality and professional accountability (Correct answer)
To eliminate the need for ongoing training

Correct answer: To ensure consistent quality and professional accountability

Professional Standards & Ethics in Pharmacovigilance Certification primarily ensures consistent quality and professional accountability, forming the foundation of competent practice in this field.

Question 15: When a post-marketing safety update reveals a new contraindication for a drug, the regulatory pathway most commonly used to change the US label is:

Annual Report update only
Changes Being Effected immediately (CBE-0) (Correct answer)
Prior Approval Supplement (PAS)
Changes Being Effected in 30 Days (CBE-30)

Correct answer: Changes Being Effected immediately (CBE-0)

Adding or strengthening a contraindication qualifies for a CBE-0 supplement, allowing the label change to be implemented immediately while the supplement is pending FDA review.

Question 16: Under 21 CFR 312.32, a sponsor must notify FDA of an IND safety report for an unexpected serious adverse reaction within what timeframe?

7 calendar days
30 calendar days
24 hours
15 calendar days (Correct answer)

Correct answer: 15 calendar days

Under 21 CFR 312.32(c)(1), sponsors must report unexpected serious adverse reactions that suggest significant risk within 15 calendar days.

Question 17: Which international guideline provides standards for the collection and reporting of adverse drug reactions?

ICH E6
FDA CFR Part 11
ICH E2A (Correct answer)
ICH M4

Correct answer: ICH E2A

ICH E2A guideline outlines the clinical safety data management of individual case safety reports (ICSRs).

Question 18: How does risk management apply to daily practice in Adverse Drug Reaction Reporting for Pharmacovigilance professionals?

Only through responding to incidents after they occur
Through proactive identification of potential hazards and implementation of preventive measures (Correct answer)
Through annual safety audits exclusively
By avoiding high-risk situations entirely

Correct answer: Through proactive identification of potential hazards and implementation of preventive measures

Effective risk management in Adverse Drug Reaction Reporting requires proactive hazard identification and preventive measures, not just reactive responses. This approach reduces incidents, improves outcomes, and protects both professionals and clients.

Question 19: A drug approved under accelerated approval has a confirmed efficacy endpoint that was used as a surrogate. Post-marketing confirmatory trials fail to show clinical benefit. What is the likely regulatory outcome?

The FDA grants a five-year extension to allow additional trials
The sponsor is permitted to continue marketing if they submit a new REMS
No regulatory action is taken because the drug was already approved
The FDA may withdraw approval using expedited withdrawal procedures (Correct answer)

Correct answer: The FDA may withdraw approval using expedited withdrawal procedures

Under the accelerated approval pathway, if confirmatory trials fail to verify clinical benefit, the FDA can withdraw approval through an expedited process without the standard hearing procedures.

Question 20: A pharmacovigilance scientist is performing a Bayesian data mining analysis on a spontaneous reporting database. Which metric is specifically associated with this Bayesian approach?

Proportional Reporting Ratio (PRR)
Reporting Odds Ratio (ROR)
Relative Risk (RR)
Information Component (IC) (Correct answer)

Correct answer: Information Component (IC)

The Information Component (IC) is a Bayesian disproportionality metric used by the WHO Uppsala Monitoring Centre in VigiBase to detect drug-event associations.

Question 21: Which standard of practice is MOST important for ensuring quality in Periodic Safety Update Reports?

Using the most advanced technology available regardless of need
Strictly adhering to the same procedure in every situation
Following evidence-based protocols while adapting to specific circumstances (Correct answer)
Minimizing documentation to focus on practical work

Correct answer: Following evidence-based protocols while adapting to specific circumstances

Question 22: What is a common challenge professionals face when applying communication & stakeholder management principles in Pharmacovigilance Certification?

Having too much support from colleagues
Balancing theoretical knowledge with practical application (Correct answer)
Excessive simplicity of industry regulations
Lack of any professional development opportunities

Correct answer: Balancing theoretical knowledge with practical application

Balancing theoretical knowledge with practical application is a well-recognized challenge, as real-world scenarios often present complexities not covered in standard training.

Question 23: Which of the following is TRUE regarding the relationship between an RMP and a PSUR?

The RMP and PSUR are entirely independent documents with no cross-reference
PSURs are only submitted for products without an RMP
The PSUR replaces the RMP once a product is approved
PSUR findings can trigger RMP updates if new risks or benefit-risk changes are identified (Correct answer)

Correct answer: PSUR findings can trigger RMP updates if new risks or benefit-risk changes are identified

PSURs evaluate the benefit-risk profile periodically, and significant new findings should prompt an RMP review and update if warranted.

Question 24: What is the primary purpose of the 'worldwide case number' (or global case ID) in an ICSR?

To record the manufacturing lot number
To uniquely identify and track the case across all submissions and follow-ups (Correct answer)
To assign a MedDRA code automatically
To indicate the regulatory authority receiving the report

Correct answer: To uniquely identify and track the case across all submissions and follow-ups

The worldwide case number is a unique identifier assigned by the company that allows tracking of the case, linking initial and follow-up reports, and preventing duplication across databases.

Question 25: According to ICH E2A, which of the following criteria is NOT required to classify an adverse event as a SUSAR?

The event must be unexpected
The event must be fatal (Correct answer)
There must be a reasonable possibility of causal relationship
The event must be serious

Correct answer: The event must be fatal

A SUSAR requires serious + unexpected + reasonable causal relationship — it does not need to be fatal; fatal events are a subset of serious events.

Question 26: What does 'listedness' refer to when assessing an adverse event in an ICSR?

Whether the adverse event is described in the current approved Reference Safety Information for the product (Correct answer)
Whether the event is coded in MedDRA
Whether the reporter is listed in the regulatory database
Whether the case has been submitted to the WHO database

Correct answer: Whether the adverse event is described in the current approved Reference Safety Information for the product

Listedness (or expectedness) is determined by comparing the reported adverse event to the Reference Safety Information (e.g., the current Investigator's Brochure or SmPC) to see if it is already described.

Question 27: A pharmaceutical company is submitting a new marketing authorization application in the EU. When must the RMP be submitted relative to the application?

Within 6 months after receiving marketing authorization
Simultaneously with the marketing authorization application (Correct answer)
Only if a CHMP opinion requests one after initial review
12 months after the first PSUR is submitted

Correct answer: Simultaneously with the marketing authorization application

The RMP must be submitted together with the marketing authorization application as an integral part of the dossier.

Question 28: Which of the following sources of data is typically NOT included in the patient exposure estimate within a PSUR?

Named patient/compassionate use programs
Sales data converted to patient-treatment episodes
Post-marketing clinical trials
Number of patients who did not tolerate the drug and discontinued (Correct answer)

Correct answer: Number of patients who did not tolerate the drug and discontinued

Patients who discontinued therapy are still part of the exposed population; they are not excluded from exposure estimates.

Question 29: A physician calls to report that three different patients in their practice developed the same serious unexpected adverse reaction to a company drug within the same week. How many ICSRs should be submitted?

One aggregate ICSR covering all three patients to avoid duplication in regulatory databases
No ICSRs until at least five cases are confirmed to establish a pattern for signal detection
Two ICSRs — one for the first reported case and one combined report for the remaining two
Three separate ICSRs, one for each individual patient (Correct answer)

Correct answer: Three separate ICSRs, one for each individual patient

Each patient constitutes a separate case and requires its own ICSR, even when cases are reported simultaneously by the same reporter; ICSRs are always individual case reports.

Question 30: How does continuing education relate to regulatory compliance & legal framework for PVC certified professionals?

It is only needed when changing employers
It is required only for entry-level practitioners
It ensures professionals stay current with evolving standards and best practices (Correct answer)
It is optional and rarely impacts practice quality

Correct answer: It ensures professionals stay current with evolving standards and best practices

Continuing education ensures PVC professionals stay current with evolving standards, technologies, and best practices in regulatory compliance & legal framework, maintaining competency throughout their careers.

Question 31: An effects table in benefit-risk assessment is BEST described as:

A regulatory submission checklist
A statistical model predicting drug response
A list of contraindications
A structured display comparing magnitudes of key benefits and risks across alternatives (Correct answer)

Correct answer: A structured display comparing magnitudes of key benefits and risks across alternatives

An effects table presents key benefits and risks side-by-side with their magnitudes and uncertainties to support transparent comparison.

Question 32: Which of the following best illustrates an 'Important Identified Risk' suitable for inclusion in Part II of an EU RMP?

Drug-induced QT prolongation confirmed by clinical trial electrocardiogram data (Correct answer)
A theoretical hepatotoxicity concern based on drug mechanism only
Lack of data in patients with severe renal impairment
A potential teratogenicity extrapolated from animal studies

Correct answer: Drug-induced QT prolongation confirmed by clinical trial electrocardiogram data

An Important Identified Risk is one where evidence of a causal association with the drug is established; QT prolongation confirmed by ECG data in clinical trials meets this standard.

Question 33: When a company receives an ICSR from a patient support program it sponsors, how should the case be classified?

Literature report
Regulatory authority report
Solicited report (Correct answer)
Spontaneous report

Correct answer: Solicited report

Reports from company-sponsored patient support programs are classified as solicited because they arise from an organized data-collection scheme, not voluntary unsolicited reporting.

Question 34: When implementing communication & stakeholder management practices, what should a PVC professional prioritize first?

Personal convenience and efficiency
Speed of completion over thoroughness
Cost reduction at all levels
Compliance with established standards and protocols (Correct answer)

Correct answer: Compliance with established standards and protocols

Compliance with established standards and protocols must be the first priority, as it ensures safety, quality, and legal adherence in professional practice.

Question 35: In a clinical trial, an investigator reports a serious adverse event that the sponsor disagrees with regarding causality. What is the correct approach for IND reporting to the FDA?

The sponsor's causality assessment overrides the investigator's, and only the sponsor's view is reported
Only the investigator's causality assessment is submitted, as they are the treating physician
The case is placed on hold pending adjudication by an independent data safety monitoring board
Both the investigator's and sponsor's causality assessments must be reported when they differ (Correct answer)

Correct answer: Both the investigator's and sponsor's causality assessments must be reported when they differ

Under 21 CFR 312.32, when the investigator and sponsor disagree on causality, both assessments must be included in the IND safety report submitted to the FDA.

Question 36: In the context of signal detection, what is a 'false positive' signal?

A confirmed causal drug-event relationship
An adverse event reported without a suspect drug
A signal detected only in post-marketing data
A statistical association that does not reflect a true causal relationship (Correct answer)

Correct answer: A statistical association that does not reflect a true causal relationship

A false positive is a statistical disproportionality that meets detection thresholds but does not represent a real drug-caused effect upon further evaluation.

Question 37: GVP Module IX defines signal management. Which of the following best describes a 'validated signal' in pharmacovigilance?

A signal that has been assessed and closed with no action required
A signal entered into EudraVigilance without follow-up needed
A signal confirmed as a causal association by a phase IV study
A signal for which the data are sufficient to justify further action such as a detailed evaluation (Correct answer)

Correct answer: A signal for which the data are sufficient to justify further action such as a detailed evaluation

A validated signal is one where the available information justifies further evaluation; it does not yet confirm causality but warrants more detailed analysis.

Question 38: What is the primary purpose of signal detection in pharmacovigilance?

To identify previously unrecognized or incompletely documented safety concerns (Correct answer)
To replace post-market clinical trials
To confirm that a drug is safe for market approval
To determine product pricing strategies

Correct answer: To identify previously unrecognized or incompletely documented safety concerns

Signal detection aims to identify new or incompletely characterized safety concerns that may require further investigation or risk minimization measures.

Question 39: Which MedDRA level is used to code adverse events for regulatory submissions?

Lowest Level Term (LLT)
High Level Term (HLT)
Preferred Term (PT) (Correct answer)
System Organ Class (SOC)

Correct answer: Preferred Term (PT)

Preferred Terms (PTs) are the primary level used to code adverse events in regulatory submissions and safety databases.

Question 40: What is a 'SUSAR' and in what regulatory context is the term most commonly used?

Suspected Unexpected Serious Adverse Reaction — used primarily in clinical trial (IND) pharmacovigilance reporting (Correct answer)
Standard Unexpected Serious Adverse Reaction — used in periodic benefit-risk evaluation reports
Sudden Unexplained Serious Adverse Reaction — used in post-marketing spontaneous report classification
Suspected Unconfirmed Serious Adverse Report — used in signal detection and validation workflows

Correct answer: Suspected Unexpected Serious Adverse Reaction — used primarily in clinical trial (IND) pharmacovigilance reporting

SUSAR stands for Suspected Unexpected Serious Adverse Reaction and is the term used in the clinical trial context to identify cases requiring expedited reporting to regulatory authorities and ethics committees.

Question 41: What is the PRIMARY purpose of continuing education requirements in Signal Detection & Analysis for PVC professionals?

Maintaining current knowledge and competency as the field evolves (Correct answer)
Fulfilling mandatory regulatory requirements only
Networking with other professionals in the field
Earning additional credentials for career advancement

Correct answer: Maintaining current knowledge and competency as the field evolves

Continuing education in Signal Detection & Analysis ensures professionals maintain current knowledge and skills as standards, technologies, and best practices evolve in the Pharmacovigilance field.

Question 42: A MAH is designing a healthcare professional (HCP) educational program as an additional risk minimization measure. Which metric best evaluates its effectiveness?

Proportion of HCPs who can correctly identify contraindications post-training (Correct answer)
Total advertising spend on the educational campaign
Number of educational materials distributed to pharmacies
Number of adverse event reports received after implementation

Correct answer: Proportion of HCPs who can correctly identify contraindications post-training

Effectiveness of educational aRMMs is best measured by behavioral or knowledge outcomes in the target population, not just material distribution.

Question 43: Under EU GVP Module IX, what is the minimum expected frequency for signal detection activities for centrally authorized products by the Marketing Authorization Holder?

Only when triggered by a health authority request or serious signal
Quarterly, aligned with PSUR submission schedules
Continuously for signals from EudraVigilance, with formal review at least monthly (Correct answer)
Annually, at the time of the PSUR data lock point

Correct answer: Continuously for signals from EudraVigilance, with formal review at least monthly

GVP Module IX requires MAHs to monitor EudraVigilance data continuously and conduct formal signal detection reviews at least on a monthly basis for CAPs.

Question 44: Which of the following is an example of a risk minimization measure?

Pricing strategy report
Annual marketing plan
Educational materials for prescribers (Correct answer)
Sales forecasting

Correct answer: Educational materials for prescribers

Educational materials for healthcare professionals and patients are part of additional risk minimization tools used beyond routine pharmacovigilance.

Question 45: Which technology trend is most likely to impact communication & stakeholder management in the PVC field in coming years?

Complete elimination of human professionals
Reduction in the need for professional certification
Return to exclusively paper-based systems
Digital tools for enhanced data collection, analysis, and reporting (Correct answer)

Correct answer: Digital tools for enhanced data collection, analysis, and reporting

Digital tools for enhanced data collection, analysis, and reporting represent the most significant and practical technology trend impacting communication & stakeholder management, augmenting rather than replacing professional expertise.

Question 46: What is the highest level in the MedDRA hierarchy?

Preferred Term (PT)
High Level Term (HLT)
System Organ Class (SOC) (Correct answer)
High Level Group Term (HLGT)

Correct answer: System Organ Class (SOC)

System Organ Class (SOC) is the highest level in MedDRA, organizing terms by broad groupings such as organ system, etiology, or manifestation site.

Question 47: What is 'missing information' in the context of an EU RMP Safety Specification?

Clinical trial data withheld by the sponsor
Gaps in knowledge about product safety in specific populations or situations not studied (Correct answer)
Adverse reactions not yet listed in the SmPC
Unreported spontaneous cases in the database

Correct answer: Gaps in knowledge about product safety in specific populations or situations not studied

Missing information refers to areas where safety data are absent or insufficient, such as use in pregnancy, elderly patients, or patients with renal impairment.

Question 48: What distinguishes an 'unexpected' adverse drug reaction from an 'expected' one in the context of clinical trial safety reporting?

The event was not predicted by the trial protocol
Unexpected events are always serious
The nature or severity is not consistent with the Investigator's Brochure (Correct answer)
Unexpected events occur more frequently than anticipated

Correct answer: The nature or severity is not consistent with the Investigator's Brochure

An unexpected ADR is one whose nature, severity, or specificity is not consistent with the reference safety information in the Investigator's Brochure.

Question 49: A sponsor receives a fatal SUSAR from an investigator site in Canada for a drug under a US IND. What is the correct regulatory action?

Hold the report until confirmation from the Canadian investigator and then submit a 30-day report
Submit a 15-day expedited report to FDA only, since the event occurred in Canada
Submit a 7-day alert report to FDA and notify all investigators via IND Safety Report within 15 days (Correct answer)
Notify the Canadian Health Authority only; FDA does not require foreign SUSAR reporting

Correct answer: Submit a 7-day alert report to FDA and notify all investigators via IND Safety Report within 15 days

Under 21 CFR 312.32, fatal SUSARs anywhere in the world trigger a 7-day alert to FDA, followed by a full 15-day expedited report and notification to all investigators.

Question 50: A company receives a serious adverse event report from a post-marketing study. Under FDA regulations, within what timeframe must they submit a 15-day Alert Report?

30 calendar days from receipt
15 calendar days from initial receipt (Correct answer)
7 calendar days from receipt
15 business days from receipt

Correct answer: 15 calendar days from initial receipt

FDA 21 CFR 314.81 requires 15-day Alert Reports for serious, unexpected post-marketing adverse drug reactions to be submitted within 15 calendar days of receipt.

Question 51: Which phase of clinical trials focuses most on assessing a drug's safety profile?

Phase III
Phase I (Correct answer)
Phase II
Phase IV

Correct answer: Phase I

Phase I trials are designed to assess the safety, tolerability, and pharmacokinetics of a drug in healthy volunteers or patients.

Question 52: Which documentation practice is most important for professional standards & ethics in the PVC field?

Documenting only when legally required
Maintaining complete, accurate, and timely records (Correct answer)
Recording only successful outcomes
Using informal notes instead of official records

Correct answer: Maintaining complete, accurate, and timely records

Maintaining complete, accurate, and timely records is crucial for accountability, quality assurance, and legal compliance in professional standards & ethics.

Question 53: Which organization is responsible for maintaining and distributing MedDRA under ICH direction?

ICH Secretariat
FDA (Food and Drug Administration)
MSSO (Maintenance and Support Services Organization) (Correct answer)
EMA (European Medicines Agency)

Correct answer: MSSO (Maintenance and Support Services Organization)

The MSSO (Maintenance and Support Services Organization) is the designated body responsible for maintaining, distributing, and providing support for MedDRA on behalf of the ICH.

Question 54: In Pharmacovigilance Certification, what role does professional standards & ethics play in ensuring client/stakeholder satisfaction?

It has no direct impact on stakeholder satisfaction
It replaces the need for direct communication
It only matters during initial certification
It builds trust through demonstrated competence and consistency (Correct answer)

Correct answer: It builds trust through demonstrated competence and consistency

Professional Standards & Ethics builds trust through demonstrated competence and consistency, which directly contributes to stakeholder satisfaction and confidence in the PVC professional.

Question 55: What is the primary difference between a 'Direct Healthcare Professional Communication' (DHPC) and a standard product label update in EU pharmacovigilance?

A DHPC replaces the SmPC permanently, while label updates are temporary
A DHPC and label update are identical in scope and timeline
A DHPC is issued only by EMA, while label updates are issued by the MAH
A DHPC is sent proactively to prescribers when an urgent safety issue requires immediate communication, while label updates follow normal variation procedures (Correct answer)

Correct answer: A DHPC is sent proactively to prescribers when an urgent safety issue requires immediate communication, while label updates follow normal variation procedures

A DHPC is a direct, urgent communication sent proactively to healthcare professionals to inform them of important new safety information, while SmPC updates follow regulatory variation timelines.

Question 56: How should a PVC professional handle a situation where regulatory compliance & legal framework protocols conflict with practical constraints?

Avoid addressing the conflict entirely
Document the conflict and seek guidance from appropriate authorities (Correct answer)
Make a unilateral decision without consultation
Always ignore the protocols in favor of practicality

Correct answer: Document the conflict and seek guidance from appropriate authorities

When protocols conflict with practical constraints, the professional approach is to document the conflict and seek guidance, ensuring transparency and compliance while working toward a resolution.

Question 57: Which field in an ICSR is used to capture the outcome of the adverse event at the time of reporting?

Reporter qualification
Patient medical history
Reaction outcome (Correct answer)
Drug indication

Correct answer: Reaction outcome

The reaction outcome field documents whether the patient recovered, is recovering, had sequelae, died, or the outcome is unknown at the time of the report.

Question 58: Which MedDRA hierarchy level is used for signal detection and regulatory submission coding of adverse events?

High Level Term (HLT)
Preferred Term (PT) (Correct answer)
Lowest Level Term (LLT)
System Organ Class (SOC)

Correct answer: Preferred Term (PT)

Preferred Terms (PTs) are the primary level used for ICSR coding, signal detection, and regulatory reporting within the MedDRA hierarchy.

Question 59: What is the purpose of Good Pharmacovigilance Practices (GVP)?

To ensure laboratory compliance
To oversee medical device quality
To manage drug prices
To monitor and improve drug safety (Correct answer)

Correct answer: To monitor and improve drug safety

GVP guidelines ensure the safety of medicinal products by defining responsibilities for pharmacovigilance systems within regulatory frameworks.

Question 60: In Bayesian signal detection using the Multi-item Gamma Poisson Shrinker (MGPS), what does the EB05 value represent?

A threshold above which signals require immediate reporting
The expected background count divided by 5
The 5th percentile of the posterior distribution of the EBGM, used as a conservative lower bound (Correct answer)
The 95th percentile confidence interval upper bound

Correct answer: The 5th percentile of the posterior distribution of the EBGM, used as a conservative lower bound

EB05 is the lower 5th percentile of the posterior EBGM distribution, meaning a signal must exceed this value (typically >2) to be considered robust.

Question 61: Which ICH guideline introduced the concept of the Periodic Benefit-Risk Evaluation Report (PBRER) to replace the traditional PSUR?

ICH E2F
ICH E2E
ICH E2D
ICH E2C(R2) (Correct answer)

Correct answer: ICH E2C(R2)

ICH E2C(R2) replaced the earlier E2C(R1) PSUR format with the PBRER, which requires an integrated benefit-risk evaluation as a core component.

Question 62: The FDA's Sentinel System primarily uses which type of data infrastructure to conduct active post-market safety surveillance?

Social media mining for patient-reported outcomes
Electronic health records and claims data from distributed data partners (Correct answer)
Spontaneous adverse event reports from MedWatch
Randomized controlled trial data from FDA-sponsored studies

Correct answer: Electronic health records and claims data from distributed data partners

Sentinel uses a distributed data network model where partners (insurers, health systems) run queries locally on EHR and claims data without sharing patient-level data centrally.

Question 63: Which provision of the FDA Safety and Innovation Act (FDASIA 2012) strengthened FDA's authority to require post-market safety studies or clinical trials?

PDUFA VI commitments
Section 505(o)(3) of the FD&C Act (Correct answer)
21 CFR 314.81(b)(2)(vi)
Section 901 — Post-market studies and clinical trials

Correct answer: Section 505(o)(3) of the FD&C Act

Section 505(o)(3) of the FD&C Act, as strengthened by FDASIA, gives FDA authority to require post-approval studies or clinical trials to assess known serious risks or new safety signals.

Question 64: Which organization is responsible for issuing GVP guidelines in the European Union?

EMA (Correct answer)
FDA
ICH
WHO

Correct answer: EMA

The European Medicines Agency (EMA) is the authority that develops and maintains GVP modules in the EU.

Question 65: Which regulatory document guides safety reporting during clinical trials?

ICH Q10
ICH E2A (Correct answer)
ICH M4
ICH E6

Correct answer: ICH E2A

ICH E2A provides guidance for clinical safety data management, particularly the reporting of adverse drug reactions in trials.

Question 66: During a post-marketing study, confounding by indication is a major concern. What does this term mean?

The indication label was incorrectly assigned during regulatory review
Multiple indications are studied simultaneously
The disease severity that drives drug prescription also affects the outcome (Correct answer)
Patients receive the wrong indication for treatment

Correct answer: The disease severity that drives drug prescription also affects the outcome

Confounding by indication occurs when the underlying disease for which a drug is prescribed is itself a risk factor for the outcome under study.

Question 67: Which documentation practice is most important for regulatory compliance & legal framework in the PVC field?

Recording only successful outcomes
Using informal notes instead of official records
Documenting only when legally required
Maintaining complete, accurate, and timely records (Correct answer)

Correct answer: Maintaining complete, accurate, and timely records

Maintaining complete, accurate, and timely records is crucial for accountability, quality assurance, and legal compliance in regulatory compliance & legal framework.

Question 68: Which statistical measure is used in Empirical Bayes Geometric Mean (EBGM) signal detection to shrink estimates toward the prior mean?

Maximum likelihood estimation without prior correction
Poisson regression with covariate adjustment
Chi-square test with Yates correction
Bayesian shrinkage toward the global reporting rate (Correct answer)

Correct answer: Bayesian shrinkage toward the global reporting rate

EBGM applies Bayesian shrinkage that pulls individual drug-event estimates toward the overall reporting rate when observed counts are low, reducing noise.

Question 69: An ICSR is received 20 days after the company becomes aware of the event. For a 15-day serious expedited report, what action is required?

Submit within 15 days of original awareness date, noting the delay
Downgrade to a non-expedited report
The report is no longer required since the deadline has passed
Submit immediately as a late report and notify the regulatory authority of the delay (Correct answer)

Correct answer: Submit immediately as a late report and notify the regulatory authority of the delay

The company must submit the overdue report as soon as possible and notify the relevant regulatory authority of the late submission, as the obligation does not disappear after the deadline passes.

Question 70: When performing signal detection on combination products, what specific analytical challenge must be addressed?

Inability to code combination products in MedDRA terminology
Drug-drug interaction confounding where each component may independently cause the adverse event (Correct answer)
Automatic exclusion of combination product reports from VigiBase
Regulatory prohibition on spontaneous reporting for combination therapies

Correct answer: Drug-drug interaction confounding where each component may independently cause the adverse event

Combination products present confounding because it is difficult to attribute the adverse event to a single component versus the combination or interaction between components.

Question 71: A MAH in the US receives an adverse event report lacking a patient identifier and a reporter. Under FDA guidance, how should this case be handled?

Discarded as it does not meet minimum criteria for valid ICSR
Processed as a valid report if at least an identifiable patient OR reporter is present along with a suspect drug and adverse event (Correct answer)
Followed up aggressively to obtain all missing information before processing
Reported to FDA within 15 days with available information noted as incomplete

Correct answer: Processed as a valid report if at least an identifiable patient OR reporter is present along with a suspect drug and adverse event

FDA requires four minimum criteria for a valid ICSR: identifiable patient, identifiable reporter, suspect drug, and adverse event — but 'identifiable' can be indirect (e.g., age/sex without name).

Question 72: In a signal evaluation process, which of the following outputs would trigger immediate regulatory action without waiting for further data?

A PRR of 1.5 based on 20 spontaneous reports of a mild rash
An increase in non-serious reports consistent with labeled events
An observational study showing a borderline odds ratio of 1.2 with wide confidence intervals
A cluster of fatal cardiac events with a strong temporal relationship to a recently approved drug (Correct answer)

Correct answer: A cluster of fatal cardiac events with a strong temporal relationship to a recently approved drug

A cluster of fatal events with strong temporal association represents an urgent safety signal that warrants immediate regulatory action such as label update, Dear Healthcare Provider letter, or market withdrawal.

Question 73: The 'Information Component' (IC) used by the WHO-UMC is based on which statistical approach?

Frequentist chi-square test
Logistic regression
Kaplan-Meier survival analysis
Bayesian confidence propagation neural network (Correct answer)

Correct answer: Bayesian confidence propagation neural network

The IC is derived from a Bayesian Confidence Propagation Neural Network (BCPNN), measuring the statistical association between a drug and an event in VigiBase.

Question 74: In Benefit-Risk Assessment, what is the FIRST step a PVC professional should take when encountering a new case or situation?

Conduct a comprehensive assessment and gather all relevant information (Correct answer)
Implement an immediate solution based on past experience
Document the situation and wait for further instructions
Consult with a supervisor before taking any action

Correct answer: Conduct a comprehensive assessment and gather all relevant information

In Benefit-Risk Assessment, a thorough initial assessment ensures all relevant factors are identified before deciding on an appropriate course of action. This systematic approach is fundamental to Pharmacovigilance practice.

Question 75: A sponsor receives an IND safety report for a fatal SAE from an investigator on Day 1. By which day must the FDA receive the expedited report?

Day 3
Day 30
Day 7 (Correct answer)
Day 15

Correct answer: Day 7

Fatal or life-threatening unexpected SUSARs in IND studies must be reported to the FDA within 7 calendar days of the sponsor's initial receipt under 21 CFR 312.32(c).

Question 76: How does risk management apply to daily practice in Benefit-Risk Assessment for Pharmacovigilance professionals?

Through proactive identification of potential hazards and implementation of preventive measures (Correct answer)
Only through responding to incidents after they occur
Through annual safety audits exclusively
By avoiding high-risk situations entirely

Correct answer: Through proactive identification of potential hazards and implementation of preventive measures

Effective risk management in Benefit-Risk Assessment requires proactive hazard identification and preventive measures, not just reactive responses. This approach reduces incidents, improves outcomes, and protects both professionals and clients.

Question 77: During a CHMP assessment of an RMP, the committee requests that a MAH upgrade a safety concern from 'potential risk' to 'identified risk.' What evidence would MOST justify this reclassification?

Meta-analysis of multiple trials demonstrating statistically significant causal association (Correct answer)
A single case report in the post-marketing period
Mechanistic plausibility based on the drug's class effects
One published case study in a non-peer-reviewed journal

Correct answer: Meta-analysis of multiple trials demonstrating statistically significant causal association

Reclassification to 'identified risk' requires robust evidence of causality, such as that provided by a meta-analysis showing a statistically significant association.

Question 78: In Pharmacovigilance Certification, what role does communication & stakeholder management play in ensuring client/stakeholder satisfaction?

It replaces the need for direct communication
It builds trust through demonstrated competence and consistency (Correct answer)
It has no direct impact on stakeholder satisfaction
It only matters during initial certification

Correct answer: It builds trust through demonstrated competence and consistency

Communication & Stakeholder Management builds trust through demonstrated competence and consistency, which directly contributes to stakeholder satisfaction and confidence in the PVC professional.

Question 79: Which term describes an adverse drug reaction that is severe, potentially life-threatening, and requires immediate medical intervention but does not result in death or permanent injury?

Life-threatening adverse event (Correct answer)
Significant medical event
Serious adverse event
Grade 4 adverse event

Correct answer: Life-threatening adverse event

A life-threatening adverse event is one in which the patient is at immediate risk of death at the time of the reaction, which is a seriousness criterion under ICH E2A.

Question 80: Which coding dictionary is the international standard for classifying adverse event terms in pharmacovigilance reporting?

WHO-ART (WHO Adverse Reaction Terminology)
SNOMED CT
MedDRA (Medical Dictionary for Regulatory Activities) (Correct answer)
ICD-10

Correct answer: MedDRA (Medical Dictionary for Regulatory Activities)

MedDRA is the internationally agreed medical terminology standard mandated by ICH and regulatory agencies worldwide for coding adverse events in safety reports.

Question 81: Which ICH guideline specifically addresses the format and content of individual case safety reports (ICSRs) submitted to regulatory authorities?

ICH E2B (Correct answer)
ICH E2D
ICH E2A
ICH E2C

Correct answer: ICH E2B

ICH E2B defines the data elements and electronic transmission standards for ICSRs, including the E2B(R3) format based on HL7 ICSR.

Question 82: What is the role of the PRAC (Pharmacovigilance Risk Assessment Committee) in the EU signal management process?

It conducts post-authorization safety studies on behalf of MAHs
It detects signals in EudraVigilance exclusively
It issues final marketing authorization decisions for new products
It evaluates signals referred by EMA or NCAs and recommends regulatory action to CHMP (Correct answer)

Correct answer: It evaluates signals referred by EMA or NCAs and recommends regulatory action to CHMP

PRAC is the EMA committee responsible for assessing and monitoring the safety of human medicines, including evaluating safety signals and recommending risk minimization measures to CHMP.

Question 83: Which WHO causality category should be applied when an event follows a reasonable temporal sequence and cannot be explained by disease or other drugs, but no rechallenge information is available?

Certain
Unlikely
Possible
Probable/Likely (Correct answer)

Correct answer: Probable/Likely

The WHO 'Probable/Likely' category applies when a plausible time relationship exists, the event is unlikely attributed to disease or other drugs, and rechallenge data is lacking or unclear.

Question 84: Which of the following best describes a key competency required for regulatory compliance & legal framework in PVC certification?

Memorization of all relevant regulations verbatim
Critical thinking and evidence-based decision making (Correct answer)
Delegation of all complex tasks to supervisors
Ability to work independently without any oversight

Correct answer: Critical thinking and evidence-based decision making

Critical thinking and evidence-based decision making is essential for regulatory compliance & legal framework, as professionals must analyze situations and apply knowledge appropriately.

Question 85: Which ICH guideline specifically addresses pharmacovigilance for biotechnology-derived products and establishes principles for immunogenicity assessment?

ICH Q5E
ICH S6(R1) (Correct answer)
ICH E2A
ICH S9

Correct answer: ICH S6(R1)

ICH S6(R1) provides preclinical safety evaluation guidance for biotechnology-derived pharmaceuticals, including immunogenicity risk assessment principles.

Question 86: Which statement BEST describes the role of the Qualified Person for Pharmacovigilance (QPPV) in risk management planning?

The QPPV signs off on all manufacturing batch records
The QPPV is responsible solely for PSUR compilation
The QPPV has overall responsibility for the pharmacovigilance system including RMP oversight (Correct answer)
The QPPV only manages spontaneous adverse event reports

Correct answer: The QPPV has overall responsibility for the pharmacovigilance system including RMP oversight

The QPPV bears overall responsibility for the pharmacovigilance system, which includes ensuring RMPs are developed, maintained, and submitted appropriately.

Question 87: Which tool is considered an ADDITIONAL risk minimization measure (aRMM) as opposed to a routine one?

Patient Information Leaflet (PIL)
Labeling updates
Summary of Product Characteristics (SmPC)
Controlled distribution program (Correct answer)

Correct answer: Controlled distribution program

Controlled distribution programs restrict prescribing or dispensing to specific settings or patients, making them additional rather than routine measures.

Question 88: A sponsor identifies a new, potentially serious risk for a drug under clinical development. Within how many calendar days must a SUSAR be reported to the FDA?

7 days for all SUSARs regardless of outcome
15 days for all serious unexpected adverse reactions
30 days for all serious adverse events
7 days for fatal/life-threatening; 15 days for other serious unexpected (Correct answer)

Correct answer: 7 days for fatal/life-threatening; 15 days for other serious unexpected

FDA regulations (21 CFR 312.32) require 7-day reporting for fatal or life-threatening SUSARs and 15-day reporting for other serious unexpected reactions.

Question 89: What does the term 'unlabeled' mean in the context of adverse event reporting for marketed products?

The adverse event is not listed in the current approved prescribing information (Correct answer)
The patient did not read the medication label
The report was submitted without a product lot number
The product has no approved label

Correct answer: The adverse event is not listed in the current approved prescribing information

An unlabeled (unexpected) adverse event is one not described in the current version of the approved prescribing information or Summary of Product Characteristics.

Question 90: In E2B(R3), what does the data element 'G.k.4.r.1a' typically capture?

MedDRA code for the adverse event
Patient's date of birth
Country of occurrence
Dose of the suspect drug (Correct answer)

Correct answer: Dose of the suspect drug

The G.k.4.r.1a data element captures the dose of the suspect or interacting drug as part of the drug dosage information block in E2B(R3).

Question 91: Which quality improvement method is most applicable to communication & stakeholder management in Pharmacovigilance Certification?

Plan-Do-Check-Act (PDCA) continuous improvement cycle (Correct answer)
Implementing changes without measuring outcomes
Ignoring feedback and maintaining status quo
Making changes only when mandated by regulators

Correct answer: Plan-Do-Check-Act (PDCA) continuous improvement cycle

The PDCA cycle is widely recognized as the most effective quality improvement method, allowing PVC professionals to systematically improve communication & stakeholder management practices.

Question 92: In the BRAT framework, what is the primary purpose of the 'value tree'?

To document patient narratives
To calculate the number needed to treat
To rank adverse events by severity
To organize and categorize key benefit and risk outcomes (Correct answer)

Correct answer: To organize and categorize key benefit and risk outcomes

The BRAT value tree hierarchically organizes key benefit and risk outcomes to ensure systematic and transparent benefit-risk assessment.

Question 93: Which technology trend is most likely to impact professional standards & ethics in the PVC field in coming years?

Complete elimination of human professionals
Digital tools for enhanced data collection, analysis, and reporting (Correct answer)
Return to exclusively paper-based systems
Reduction in the need for professional certification

Correct answer: Digital tools for enhanced data collection, analysis, and reporting

Digital tools for enhanced data collection, analysis, and reporting represent the most significant and practical technology trend impacting professional standards & ethics, augmenting rather than replacing professional expertise.

Question 94: What distinguishes a 'follow-up' ICSR from an 'initial' ICSR?

It is always submitted within 7 days
It is filed by a different reporter
It only covers fatal outcomes
It contains new or updated information on a previously reported case (Correct answer)

Correct answer: It contains new or updated information on a previously reported case

A follow-up ICSR provides additional or corrected information for a case that has already been reported, linked by the same case identifier.

Question 95: What is the key difference between a 'follow-up' report and an 'amendment' in ICSR case management?

A follow-up changes the causality assessment; an amendment changes the seriousness classification
A follow-up is required within 7 days; an amendment has no time limit
A follow-up adds new information to an ongoing case; an amendment corrects errors in a previously submitted report (Correct answer)
A follow-up is submitted to local authorities; an amendment is submitted to international agencies

Correct answer: A follow-up adds new information to an ongoing case; an amendment corrects errors in a previously submitted report

A follow-up report provides new or updated clinical information about an existing case, while an amendment corrects factual errors in a previously submitted ICSR.

Question 96: Under ICH E2C(R2), the Periodic Benefit-Risk Evaluation Report (PBRER) must include which of the following?

A line listing of all adverse events ever reported
A comparison with competitor products
Financial projections for the product
An integrated benefit-risk evaluation summarizing new findings and their impact on the overall benefit-risk balance (Correct answer)

Correct answer: An integrated benefit-risk evaluation summarizing new findings and their impact on the overall benefit-risk balance

ICH E2C(R2) requires the PBRER to include an integrated benefit-risk evaluation that synthesizes all cumulative data and assesses the current benefit-risk profile.

Question 97: A pharmacovigilance team discovers that a drug's real-world use pattern includes widespread off-label prescribing to pregnant women. What is the MOST appropriate post-marketing surveillance response?

Conduct a retrospective chart review limited to one hospital system
Issue a press release advising against off-label use and take no further action
Establish a pregnancy registry to prospectively collect safety data in this exposed population (Correct answer)
File a patent extension to include the pregnancy indication

Correct answer: Establish a pregnancy registry to prospectively collect safety data in this exposed population

A pregnancy registry is the gold-standard active surveillance method for collecting prospective, real-world safety data on drug exposure during pregnancy.

Question 98: What is the minimum disproportionality threshold commonly used with the Reporting Odds Ratio (ROR) to flag a potential signal?

ROR > 1.0 with 95% CI lower bound > 1 (Correct answer)
ROR > 1.5 with p < 0.05
ROR > 3.0 regardless of CI
ROR > 2.0 with any CI

Correct answer: ROR > 1.0 with 95% CI lower bound > 1

A signal is typically flagged when the ROR exceeds 1.0 and the lower bound of the 95% confidence interval is also above 1.

Question 99: What is the significance of peer review in professional standards & ethics for PVC professionals?

It is only relevant for newly certified professionals
It promotes accountability, knowledge sharing, and quality improvement (Correct answer)
It replaces the need for self-assessment
It is primarily used for disciplinary purposes

Correct answer: It promotes accountability, knowledge sharing, and quality improvement

Peer review promotes accountability, knowledge sharing, and quality improvement by allowing PVC professionals to benefit from collective expertise and identify areas for growth.

Question 100: A pharmaceutical company must submit a PSUR/PBRER to the EMA at what frequency for a product that has been on the market for 3 years without safety concerns?

Every 3 years unless otherwise specified in the EURD list (Correct answer)
Annually for the first 5 years post-approval
Only when a safety signal is detected
Every 6 months regardless of time on market

Correct answer: Every 3 years unless otherwise specified in the EURD list

The EMA's EURD (European Union Reference Dates) list specifies submission frequency; products without ongoing concerns typically move to 3-year cycles.

Pharmacovigilance Certification (PVC)

The Pharmacovigilance Certification (PVC) validates professionals in drug safety monitoring, adverse event reporting, signal detection, and regulatory compliance across global pharmacovigilance frameworks including FDA, EMA, and ICH guidelines.

Questions

35 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds